touchENDOCRINOLOGY caught up with Prof Gian Paolo Fadini (University Hospital of Padova, Italy) virtually during the EASD Annual Meeting 2021 conference to discuss the real-world data from the RESTORE-2 study.
1. What have randomized controlled trials taught us about the efficacy and safety of second-generation basal insulins? (00:18-01:31)
2. What were the aims, design and inclusion criteria of your study? (01:31-02:44)
3. What were the baseline characteristics of the study cohort? (02:44-03:34)
4. What were the primary and secondary outcome measures and how well were they achieved? (03:34-04:45)
5. What were the conclusions of the investigators and what questions remain unanswered? (04:45-05:57)
Speaker Disclosure: Gian Paolo Fadini is a consultant for Novo Nordisk, Sanofi, Lilly and Abbott. He has received lecture fees from Abbott, Astra Zeneca, Boehinger, Lilly, MSD, Novo Nordisk, Takeda and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Louise Taylor.
Filmed in coverage of the EASD Annual Meeting 2021
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022
We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research highlights in diabetes and what to look out for in 2023. Questions What are the key clinical highlights from 2022 in the field of diabetes? (0:16) What are the hot topics and […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!